Clinical Trials
2 trialsNCT05360368 2022-05-05
HLX07(Anti-EGFR mAb) in Patients With Advanced or Metastatic Solid Tumors
Shanghai Henlius Biotech
Phase 1 Unknown
NCT02648490 2019-07-30
An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of HLX07,in Patients With Advanced Solid Cancers
Henlix, Inc
Phase 1 Completed